Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02459886 · ClinicalTrials.gov registry record · Phase 1
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02459886 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 66 participants.
The verdict
NCT02459886, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of a range of single BIIB054 doses, administered as a single intravenous (IV) infusion, in healthy participants and participants with early Parkinson's disease (PD). Secondary objectives of the study are to assess the serum pharmacokinetics (PK) profile of BIIB054 after single-dose administration and to evaluate the immunogenicity of BIIB054 after single-dose administration.
Interventions
- DRUG Placebo
- DRUG BIIB054
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2017-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02459886
The ClinicalTrials.gov registry entry for NCT02459886 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02459886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02459886 about?
NCT02459886 is a clinical study titled "Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease". The primary objective of the study is to evaluate the safety and tolerability of a range of single BIIB054 doses, administered as a single intravenous (IV) infusion, in healthy participants and participants with early Parkinson's disease (PD). Secondary objectives of the study are to assess the seru...
What is the current status of trial NCT02459886?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-07-01. Estimated completion is 2017-11-20.
What interventions are being tested in trial NCT02459886?
The interventions under investigation include: Placebo (DRUG), BIIB054 (DRUG).
Who is sponsoring clinical trial NCT02459886?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.